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Abstract
Background: Criteria for admitting patients with incurable diseases to the medical intensive care unit (MICU)
remain unclear and have ethical implications.
Methods: We retrospectively evaluated MICU outcomes and identified risk factors for MICU mortality in
consecutive patients with advanced lung cancer admitted to two university-hospital MICUs in France between
1996 and 2006.
Results: Of 76 included patients, 49 had non-small cell lung cancer (stage IIIB n = 20; stage IV n = 29). In 60
patients, MICU admission was directly related to the lung cancer (complication of cancer management, n = 30;
cancer progression, n = 14; and lung-cancer-induced diseases, n = 17). Mechanical ventilation was required during
the MICU stay in 57 patients. Thirty-six (47.4%) patients died in the MICU. Three factors were independently
associated with MICU mortality: use of vasoactive agents (odds ratio [OR] 6.81 95% confidence interval [95%CI]
[1.77-26.26], p = 0.005), mechanical ventilation (OR 6.61 95%CI [1.44-30.5], p = 0.015) and thrombocytopenia (OR
5.13; 95%CI [1.17-22.5], p = 0.030). In contrast, mortality was lower in patients admitted for a complication of
cancer management (OR 0.206; 95%CI [0.058-0.738], p = 0.015). Of the 27 patients who returned home, four
received specific lung cancer treatment after the MICU stay.
Conclusions: Patients with acute complications of treatment for advanced lung cancer may benefit from MCIU
admission. Further studies are necessary to assess outcomes such as quality of life after MICU discharge.
Background
Lung cancer is the second most common malignancy
(after prostate cancer in males and breast cancer in
females) in the USA, and remains the leading cause of
cancer-related death in both men and women worldwide
[1]. However, the 5-year survival rate (all stages combined)
is only 16%, and ranges from 50% in localized cancer to
3% in metastatic cancer [1]. Despite this poor prognosis,
patients with lung cancer are increasingly admitted to
medical intensive care units (MICUs) for critical illnesses
related either to the underlying malignancy (regardless
of the cancer stage) or to co-morbidities [2-4]. Previous
studies showed poor outcomes in lung cancer patients
admitted to the MICU and most notably those requiring
mechanical ventilation [3-5]. Nevertheless, overall survival
rates in these patients have improved over the last decade
[2,6,7]. Three factors may have contributed to this wel-
come trend: (i) the ever-increasing number of new treat-
ments for solid tumors, (ii) earlier admission to the MICU
with the use of new techniques such as non-invasive venti-
lation (NIV) and aggressive management of septic shock
[8,9]; (iii) improved selection of patients likely to benefit
from MICU admission [10-12].
However, the patient populations in most of the pre-
vious studies [2,3,7,10,12-15] were relatively heteroge-
neous in terms of disease stage. To the best of our
knowledge, very few studies focused specifically on
MICU outcomes of patients with advanced lung cancer
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that is, patients for whom no potentially curative surgi-
cal procedure was available. Given the scarcity of health-
care resources, particularly during the current period of
economic crisis, careful attention must be directed to
allocating resources in compliance with the principle of
distributive justice. MICU admission is costly, and
selecting patients who are likely to benefit constitutes
good husbandry of public resources. In addition, the
patient and family should not be unnecessarily exposed
to the burden associated with an ICU stay. To select
patients for MICU admission, information on factors
associated with MICU mortality is needed.
Here, our primary objective was to assess the outcome
of patients with advanced lung cancer who were
admitted to the MICU. We also looked for factors asso-
ciated with mortality. To meet these objectives, we per-
formed a multicenter retrospective study of patients
admitted to two university-hospital MICUs.
Methods
This study was performed in the MICUs of the Amiens
and Caen University Hospitals (France), which admit
380 and 640 patients per year on average, respectively.
Both MICUs are managed by full-time faculty members.
The study was approved by the local independent ethics
committee called “CEERNI” which is the “Amiens Ethi-
cal committee of non interventional research”, which is
affiliated with CPP Nord Ouest II.
Patients
We retrospectively reviewed the medical records of lung
cancer patients admitted to the study MICUs between
January 1996 and December 2006. Consecutive adults
(18 years or older) with a previous diagnosis of lung can-
cer who were admitted to the MICUs during the study
period were potentially eligible. MICU admission deci-
sions were made by the senior intensivists often after dis-
cussion with the oncologist. Patients with lung cancer
diagnosed and/or staged only after MICU admission
were not eligible. Among potentially eligible patients, we
identified those advanced lung cancer, defined as lung
cancer for which no potentially curative surgical options
were available, that is, localized or disseminated stage
IIIB or IV non-small cell lung cancer (NSCLC) according
to the Mountain classification [16] or small cell lung can-
cer (SCLC)). We excluded patients those lung cancer had
been in remission for more than 5 years and those with
MICU stay durations shorter than 24 hours, except if
they died in the MICU (e.g., after admission at night fol-
lowed by treatment limitation decisions on the next day).
We also excluded patients admitted to the MICU for
postoperative care, as the study MICUs admit very few
postoperative patients whose characteristics differ con-
siderably from the overall MICU population. For patients
admitted more than once to either MICU, only the first
admission was considered.
We collected demographic information (age and gen-
der), lung cancer stage and histological type, and cancer
treatments (if any) received in the MICU. Within
24 hours after MICU admission, we recorded smoking
history, co-morbidities, WHO performance status, the
Simplified Acute Physiology Score (SAPS) II, and the
Acute Physiology and Chronic Health Evaluation
(APACHE) II score [17,18]. For each patient, we com-
puted the Charlson co-morbidity index (CCI) without
taking the presence of lung cancer into account [19].
The CCI includes 19 major disease groups. We defined
three CCI categories: low (CCI = 0), mid-range (CCI =
1-2), and high (CCI≥3).
Reasons for ICU admission
We used the clinical and laboratory data in the charts to
determine the main reason for MICU admission (infec-
tion with or without bone narrow failure, heart failure,
non-infectious pulmonary disorder or neurological fail-
ure). Laboratory data obtained within 24 h of admission
were recorded; they included the hemoglobin level,
white blood cell count, platelet count, blood urea nitro-
gen level, serum creatinine, serum lactate and serum
electrolytes, liver function tests, arterial blood gas values
and serum and blood results.
We classified reasons for MICU admission into four
groups: i) reasons unrelated to the lung cancer (e.g.
cardiac dysrhythmia, myocardial infarction, or renal
infection), ii) complications of cancer management (e.g.
chemotherapy-induced bone narrow failure, acute heart
failure during chemotherapy, or bleeding during
bronchoscopy) iii) events related to cancer progression
(e.g. superior vena cava syndrome), and iiii) events
induced by the lung cancer (e.g., pulmonary embolism).
Organ failures at MICU admission
For each patient, we recorded the type and number of
organ failures at MICU admission as follows: (i) acute
renal failure (definition used by Soares et al [4]) as creati-
nine > 120 μmol/l and uremia >8 mmol/l or creatinine
clearance (Cockcroft) <60 ml/min; (ii) acute respiratory
failure defined as respiratory rate >25/minute, cyanosis,
clinical symptoms of respiratory distress, or PaO2/FiO2
<300 mmHg; (iii) hemodynamic failure defined as a need
for vasoactive agents (norepinephrine, dobutamine, or epi-
nephrine); (iv) neurological failure defined as a Glasgow
Coma Scale score< 10 or subjective criteria such as confu-
sion, decreased responsiveness, or coma in the absence of
sedation; and (vi) bone narrow failure: defined as a white
blood cell count <2000/mm3 and/or platelet cell count
<100 000/mm3, and/or haemoglobin < 10 g/dL. Sepsis was
diagnosed using the criteria developed at the American
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College of Chest Physicians/Society of Critical Care Medi-
cine consensus conferences [20].
MICU management
We recorded the following data on management in the
MICU: use, start time and duration of invasive mechani-
cal ventilation and/or NIV; vasoactive agents; antibiotics
and other anti-infectious drugs; hemodialysis; and the
anti-cancer treatments.
Outcome
We determined mortality at the end of the MICU stay
and at the end of the hospital stay. Follow-up time was
computed from MICU admission to death, discharge or
January 1, 2008, whichever came first.
Statistical analysis
The statistical analysis was performed using SPSS 12.0
software (SPSS Inc., Chicago, IL, USA). Unless otherwise
stated, continuous quantitative variables were described as
the mean ± standard deviation and ordinal variables as the
number and percentage. To identify variables indepen-
dently associated with death, we performed a univariate
comparative analysis using Fisher’s exact test for ordinal
variables and the Student t test or Kruskal-Wallis non-
parametric test for continuous variables. Given the long
inclusion period (11 years), we checked for a period effect.
We also looked for a centre effect. Variables with p-value
equal to/or lower than 0.1 by univariate analysis (except
SAPS II and Apache II) were then subjected to backward
stepwise logistic regression analysis. Variables were for-
mally tested for collinearity. When variables were colli-
near, we used clinical judgement to select only one
variable for inclusion in the model (e.g., we included
mechanical ventilation and therefore did not include
PaO2/FiO2, or acute respiratory failure). Seven variables
were finally included in the model. The overall fit of our
binary regression model was assessed using the Hosmer
and Lemeshow chi-square test of goodness of fit. P-values
lower than 0.03 (Bonferroni correction for multiple ana-
lyses) were considered statistically significant. A univariate
survival analysis was performed using the Kaplan-Meier
nonparametric method to calculate crude cumulative sur-
vival after MICU admission. The end point was April 1,
2009. Percentages were computed using the total number
of patients in the overall study population or relevant
group as the denominator unless otherwise specified
Results
Population
Between January 1, 1996, and December 31, 2006, there
were 210 admissions of patients with lung cancer in the
two study MICUs. Of these admissions, 134 were
excluded from the study, for the following reasons:
diagnosis of lung cancer during the MICU stay (n = 45),
lung cancer staging during or after the MICU stay (n =
38); previously diagnosed stage I, II, or IIIA NSCLC
(n = 43); or repeat admission during the study period
(n = 8 admissions in 6 patients).
The remaining 76 patients (69 males) met the inclusion
criteria and constituted the study population. Among
them, 17 were admitted during the first 6 study years and
59 during the last 5 study years. Table 1 reports the main
patient characteristics. Mean age was 63 ± 10 years and
mean body mass index (available for 29 patients) was
26 ± 4 kg/m2. The diagnosis was NSCLC in 49 patients
(stage IIIB in 20 and stage IV in 29) and SCLC in
29 patients (extensive in 18 and localized in 11); 2 patients
had both NSCLC and SCLC. NSCLC histology was squa-
mous cell carcinoma in 30 patients, adenocarcinoma in
14, and undifferentiated carcinoma in 5. Co-morbidities
were reported in 47 patients including 25 with a mid-
range CCI values and 22 with a high CCI values. Median
CCI was 1.5 (range 0-7). Before MICU admission, 50
patients received specific chemotherapy and/or radio-
therapy for lung cancer (Table 1). The mean time interval
from lung cancer diagnosis to MICU admission was 117
± 154 days (median: 50 days).
Main reasons for MICU admission
The main reasons for MICU admission are listed in
Table 2. Acute respiratory failure was the most common
organ dysfunction (80%). Admission was also variously
due to an infection (41 patients), acute respiratory fail-
ure unrelated to infection (28 patients), heart failure
(in 7 patients), neurological failure (in 4 patients), and
pulmonary embolism (2 patients).
In 60 patients, MICU admission was directly related to
lung cancer. Reasons for MICU admission in these 60
patients were as follows: (i) complication of cancer man-
agement in 30 patients (adverse events related to lung
cancer treatment such as acute heart failure after che-
motherapy, chemotherapy-induced bone marrow failure,
pneumothorax after central venous catheter insertion,
radiation-induced pneumonitis [n = 25] and adverse
events related to investigations used to monitor the
treatment, such as bleeding during bronchoscopy [n =
5]); (ii) cancer progression in 14 patients; and (iii) lung
cancer-induced events (e.g. pulmonary embolism or
hemoptysis) in 17 patients.
Table 3 reports the main clinical and laboratory
features in the patients at MICU admission.
Patient management in the MICU
Median [range] MICU stay length was 4.0 [1-178] days
(Table 3). During the MICU stay, 57 patients received
mechanical ventilation. Of these, 18 (4/17 in 1996-2001
and 14/59 in 2002-2006) received NIV and 50 received
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invasive ventilation (after failed NIV in 11 patients). The
mean duration of invasive ventilation was 9.9 ± 14 days
[1-65]. Vasoactive agents were required in 25 patients.
Seven patients underwent hemodialysis and 57 received
antibiotics. Specific lung cancer treatment was given in
34 cases and consisted of chemotherapy (n = 4), corticos-
teroid therapy for superior vena cava syndrome (n = 7),
growth factor therapy for chemotherapy-induced neutro-
penia (n = 7), red blood cell or platelet transfusions for
chemotherapy-related anemia or thrombocytoaenia (n =
19) and bronchial artery embolization (n = 2).
Outcomes
Of the 76 patients, 36 died in the MICU (47.4%) and 13
died after MICU discharge but before hospital discharge
(49/76, 64.5%). In the 27 patients who returned home,
the median [95%CI] survival time after MICU discharge
was 157 [0-701] days, with 15 patients alive on day 60
and 10 on day 120 (Figure 1). Two patients were long-
term survivors (still alive at last follow-up after 54 and
107 months, respectively). Four patients underwent lung
cancer treatment after MICU discharge.
Factors predicting for MICU mortality
We found no period effect (mortality 41.2% in1996-2001
vs. 49.2% in 2002-2006, p = 0.38) or centre effect (p =
0.15). In the univariate analysis (Tables 1, 2 and 3), age,
gender and co-morbidities did not influence MICU
mortality. A history of radiotherapy was associated with
a significantly higher mortality rate (p = 0.05). Patients









Age (years), mean ± SD 62.95 ± 9.9 62.94 ± 9.7 62.96 ± 10.3 0.99
Males, n (%) 69 (90.8) 36 (90) 33 (91.7) 0.56
Period: before January 1, 2002 17 (22.4) 10 (25) 7 (19.4) 0.36
Co-morbidities
Smoking, n (%) 71 (95.9) 39 (97.5) 32 (94.1) 0.43
CCI, mean ± SD
[range]





CCI Low, n (%) 13 (32.5) 14 (35) 0.83
Mid-range, n (%) 14 (35) 11 (27.5)
High, n (%) 13 (32.5) 11 (27.5)
COPD, n (%) 24 (32) 12 (30) 12 (33) 0.42
Chronic respiratory failure, n (%) 4 (5.3) 3 (7.5) 1 (2.7) 0.37
Diabetes, n (%) 9 (11.8) 5 (12.5) 4 (11.1) 0.57
Non pulmonary neoplasm, n (%) 16 (21) 10 (25) 6 (16,6) 0.28
Lung cancer
NSCLC, n (%) 49 (64.5) 28 (70) 21 (58.3) 0.21
Squamous cell carcinoma, n (%) 30/49 (61,2) 18/29 (62.1) 12/20 (60) 0.56
Adenocarcinoma, n (%) 14/49 (28.6) 7/29 (24.1) 7/20 (35) 0.30
Undifferentiated carcinoma, n (%) 2 (4.1) 2/29 (6.9) 0 0.34
SCLC, n (%) 29 (38.2) 14 (35) 15 (41.7) 0.35
Stage*
NSCLC IIIB, n (%) 20/49 (40.8) 10/28 (35.7) 10/21 (47.6) 0.29
NSCLC IV, n (%) 29/49 (59.2) 18/28 (64.3) 11/21 (52.4) 0.29
Localized SCLC, n (%) 11/29 (37.9) 6/14 (42.9) 5/15 (33.3) 0.44
Disseminated SCLC, n (%) 18/29 (62.1) 8/14 (57.1) 10/15 (66.7) 0.44
Metastasis, n (%) 45 (59.2) 24 (60) 21 (58.3) 0.53
Lung cancer treatment
Chemotherapy, n (%) 43 (56.5) 19 (47.5) 24 (66.7) 0.073
Radiotherapy, n (%) 22 (28.9) 8 (20) 14 (38.9) 0.05
Surgery, n (%) 6 (7.9) 2 (5) 4 (11) 0.28
Percentages are relative to the total number of patients (n = 76 patients for the overall population, n = 36 for the MICU non survivors and n = 40 for the MICU
survivors) unless otherwise specified. *Two patients had both NSCLC and SCLC.CCI: Charlson Comorbidity Index; NSCLC: Non small cell lung cancer; SCLC: small
cell lung cancer; MICU: medical intensive care unit. Metastasis means extensive SCLC or stage IV NSCLC.
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Causes of reasons for admissions
Not related to lung cancer 16 (21.1) 8 (20) 8 (22.2) 0.51
Related to lung cancer 60 (78.9) 32 (80) 28 (77.8) 0.51
Complication of cancer management, n (%) 30 (39.5) 20 (50) 10 (27.8) 0.04
Cancer progression, n (%) 14 (18.4) 7 (17.5) 7 (19.4) 0.53
Lung cancer-induced events, n (%) 17 (22.4) 6 (15) 11 (30.6) 0.089
Reasons for admission
Infection, n (%) 41 (53.9) 15 (37.5) 26 (72.2) 0.002
Respiratory infection, n (%) 31 (40.8) 10 (25) 21 (58.3) 0.003
Sepsis with aplasia, n (%) 12 (15.8) 6 (15) 6 (16.7) 0.54
Heart failure, n (%) 7 (9.2) 3 (7.5) 4 (11.1) 0.44
Noninfectious pulmonary disorders, n (%) 28 (36.8) 18 (45) 10 (27.8) 0.09
Neurological failure, n (%) 4 (5.3) 3 (7.5) 1 (2.8) 0.35
Pulmonary embolism, n (%) 2 (2.6) 1 (2.5) 1 (2.8) 0.72
MICU: Medical Intensive Care Unit.
Percentages are relative to the total number of patients (n = 76 for the overall population, n = 36 for the MICU nonsurvivors, and n = 40 for the MICU survivors)
unless otherwise specified.
Table 3 Clinical and laboratory characteristics at admission to the medical intensive care units in the overall








SAPS II 43 ± 16.5 40 ± 13 46 ± 19 0.14
Apache II 22 ± 7.7 21 ± 6.8 23.5 ± 8.5 0.11
Blood cell count (/mm3) 11616 ± 8688 12899 ± 9250 10226 ± 7931 0.18
Hemoglobin (g/dL) 10.7 ± 2.2 10.5 ± 2.3 10.9 ± 2.2 0.4
Platelet count (x1000/mm3) 240 ± 236 304 ± 294 173 ± 126 0.016
Platelet count ≤ 100 000/mm3, n (%) 19 (25.7) 4 (10.5) 15 (41.7) 0.002
Calcium (mmol/L), 2.1 ± 0.1 2.11 ± 0.19 2.08 ± 0.24 0.54
Albumin (g/L) 25 ± 6.4 27 ± 6 23 ± 6 0.14
Albumin ≤ 25 g/L, n (%) 16 (51.6) 4 (30.8) 12 (66.7) 0.05
PaO2/FiO2 177 ± 102 201 ± 104 149 ± 93 0.05
Number of organ failures 2 ± 1.2 1.7 ± 1 2.3 ± 1.3 0.036
Acute respiratory failure, n (%) 66 (86.8) 30 (75) 36 (100) 0.001
Mechanical ventilation, n (%) 56 (73.7) 23 (57.5) 33 (91.7) 0.001
NIV, n (%) 17 (22.4) 6 (15) 11 (30.6) 0.089
Invasive ventilation, n (%) 50 (65.8) 19 (47.5) 31 (86.1) <0.0001
Time on mechanical ventilation (days) 9,8 ± 14 12 ± 17 8,5 ± 12,4 0.41
Need for vasoactive agents, n (%) 25 (32.9) 5 (12.5) 20 (55.6) <0.0001
Acute renal failure, n (%) 26 (34.6) 11 (27.5) 15 (41.7) 0.14
hemodialysis, n (%) 7 (9.2) 2 (5) 5 (13.9) 0.17
Neurological failure, n (%) 16 (21.1) 8 (20) 8 (22.2) 0.52
Chemotherapy in the ICU, n (%) 4 (5.5) 1 (2.7) 3 (8.3) 0.29
Corticosteroids in the ICU, n (%) 7 (9.3) 5 (12.5) 2 (5.7) 0.27
MICU: Medical Intensive Care Unit; SAPS II Simplified Acute Physiology Score; Apache II Acute Physiology and Chronic Health Evaluation; NIV: Non invasive
ventilation.
Percentages are relative to the total number of patients (n = 76 for the overall population, n = 36 for the MICU nonsurvivors, and n = 40 for the MICU survivors)
unless otherwise specified. Quantitative data are expressed as mean ± standard deviation.
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with SCLC and those with advanced NSCLC did not dif-
fer in terms of the mortality rate. Patients admitted to
the MICU for complications of cancer management had
a lower mortality rate than patients admitted for other
reasons (33.3% vs. 56.5% respectively, p = 0.04). Infec-
tion was associated with higher mortality (72.2% vs
37.5% in non-infected patients, p = 0.002). The SAPS II
and the APACHE II severity scores did not significantly
predict MICU mortality. Laboratory findings that signifi-
cantly predicted mortality by univariate analysis were
albumin level, thrombocytopenia, and PaO2/FiO2. A
need for mechanical ventilation or vasoactive agents was
associated with higher mortality rates (59% vs 15%, p <
0.0001) and 80% vs 31% p < 0.0001), respectively). Of
the four patients who received chemotherapy in the
MICU, three died during their stay.
The multivariate analysis identified three factors inde-
pendently associated with higher MICU mortality: the
use of vasoactive agents (odds ratio [OR] 6.81, 95%confi-
dence interval [95%CI] 1.77-26.26, p = 0.005), require-
ment for mechanical ventilation (OR 6.61 95% CI [1.44-
30.5], p = 0.015) and platelet count below 100,000/mm3
(OR 5.13, 95%CI [1.17-22.5]; p = 0.030). In contrast,
admission for a complication of cancer management
was associated with lower mortality (OR 0.206, 95% CI
[0.058-0.738], p = 0.015).
Discussion
A large proportion of cancer patients experience acute
life-threatening episodes related to their malignancy,
treatment or co-morbidities. Until recently, MICU
admission of patients with advanced cancer was contro-
versial and generally discouraged [21]. However, over
the last decade, several studies found increased survival
rates in this population [2,7,8,14,22]. Advances in both
oncology and intensive care may have contributed
improved survival rates, along with better selection of
the patients most likely to benefit from MICU admis-
sion [23].
Our study has several limitations. We used a retro-
spective design and were therefore unable to determine
the criteria used to select patients for MICU admission.
Consequently, we cannot assess the selection bias
induced by MICU triage process. In all likelihood, some
patients with advanced lung cancer and life-threatening
events were deemed too sick to benefit from MICU
admission. Indeed, many of our patients had a WHO
performance status of 2 or less. Second, the two study
MICUs may have differed regarding their patient selec-
tion criteria. Third, patients were included over an
11-year period, during which the management of lung
cancer improved. However, we found no evidence of a
significant period effect. Finally, our small sample size
(n = 76) produced limited statistical power. Indeed, to
have a homogeneous population, we should have
excluded 134 patients. Unfortunately, we have no data
in term of outcome after MICU stay about these 134
patients.
To the best of our knowledge, data on patients with
advanced lung cancer admitted to the MICU are scant.
Most of the previous studies were done in highly het-
erogeneous populations [4,13,14]. Our study is the first
to focus exclusively on MICU admission of patients
with advanced lung cancer and to classify reasons for
MICU admission according to their link with lung
cancer.
In our highly selected population, we found an MICU
mortality rate of 47.4% and an in-hospital mortality rate
of 64.5%. These results are in accordance with the data
recently reported by Reichner et al. (43% MICU mortal-
ity and 60% hospital mortality) [24], Soares et al. (44%
MICU mortality and 60% hospital mortality) [4], and
Rocques et al [7]. However, our patients had more
advanced disease than those in the earlier studies, sug-
gesting that, MICU and hospital mortality rates may
have improved as it is noticed the other recent studies
(See additional file 1). The number of patients with
advanced lung cancer admitted to the study MICUs
increased over the study period, from 17 during the first
6 years to 59 during the last 5 years. The absence of a
significant period effect may be related to the small
sample size.
Mortality rates in lung cancer patients admitted to the
MICU have decreased over time. In early studies,
Figure 1 Cumulative survival of the 27 patients who went back
home after the stay in the medical intensive unit. MCIU =
medical intensive care unit. Follow-up is counted from MICU
discharge.
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mortality ranged from 75% to 91% [5,13,25]. Although
Adam et al. [2] recently reported an MICU mortality
rate of only 22%, only 49% of their patients required
mechanical ventilation (versus 75% in our study), and
mortality was highest in the mechanically ventilated
patients. Moreover, the study by Adam et al included
patients with all stages of lung cancer.
In our study, MICU mortality was not significantly
influenced by age, gender or co-morbidities). A history
of thoracic radiotherapy was associated with a signifi-
cantly higher mortality, suggesting a link between radia-
tion-induced pneumonitis and acute respiratory failure.
In contrast to a report by Reichner et al [24] that stage
IV NSCLC was independently associated with higher
mortality, we found no significant influence on MICU
mortality of the lung cancer characteristics (e.g., NSCLC
vs. SCLC, NSCLC histology, and type of metastasis).
Neither did we find any significant difference in mortal-
ity between patients who had recently started cancer
treatment and patients treated for longer periods.
In line with the previous studies, we found that short-
term mortality was mainly related to the severity of
organ dysfunction and not to the characteristics of the
malignancy [2,4,5,12,13,24]. In our univariate analysis,
the main predictors of mortality were the number of
organ failures, need for vasoactive agents, and need for
invasive mechanical ventilation. Admission for an infec-
tion was also associated with higher mortality. This find-
ing may reflect patient selection, as patients with
treatment-limitation decisions were not admitted to the
MICUs as such EOL care measures are implemented
only on the wards in our institutions, and as all patients
who were admitted at night and who had treatment-lim-
itation decisions taken the next day were excluded.
As reported elsewhere, the SAPS II and APACHE II
score did not significantly predict MICU mortality in
our patients with advanced lung cancer: similar results
have been reported for the SAPS III and APACHE III
score [2,7,26]. These scores underestimate mortality and
do not reliably predict MICU mortality in patients with
malignancies. Interestingly, several laboratory character-
istics were associated with higher mortality in our study.
In the multivariate analysis, thrombocytopenia was sig-
nificantly associated with higher mortality.. We have no
explanation to this finding. The medical charts did not
contain enough information to determine the causes of
thrombocytopenia in our patients. Moreau et al. also
reported that thrombocytopenia had prognostic signifi-
cance in a large cohort of MICU patients [27], and the
platelet count is included in the SOFA score. Moreover,
thrombocytopenia is considered a marker of cancer-
related coagulation abnormalities [28,29]. We believe
that the platelet count should be included in new
scoring systems, as classic severity scores are notoriously
unreliable.
The other two variables available at admission and
independently associated with MICU mortality by multi-
variate logistic regression were a need for vasoactive
agents and a need for mechanical ventilation. Admission
for complications of cancer management was indepen-
dently associated with lower MICU mortality. One pos-
sible explanation is that these complications are acute
events that often respond promptly to treatment. An
example is acute heart failure during chemotherapy.
In addition to data on mortality, we need information
on outcomes in survivors after MICU and hospital dis-
charge. Postdischarge survival is strongly dependent on
the malignancy and its treatment. At MICU discharge, a
recovery period of several weeks is often needed before
chemotherapy can be given. In our study, median survi-
val in the 27 patients who returned home was 157 days,
with only 15 patients alive on day 60 and 10 on day
120. However, 2 patients achieved long-term survivals.
We did not assess postdischarge quality of life, which
was probably severely impaired. Of 10 patients who
were potentially eligible for further cancer chemother-
apy, 6 had WHO performance status scores greater than
2; thus, only 4 patients received further chemotherapy.
These data emphasize the need for appropriate patient
selection to MICU admission and, consequently, they
have ethical implications. Ideally, outcome evaluations
in future studies should include parameters other than
mortality, such as quality of life and eligibility for cancer
treatment after the MICU stay.
Conclusions
In conclusion, we found that, the only factor predicting
lower mortality was admission for complications of lung
cancer treatment. MICU mortality was not influenced
by the type of cancer (SCLC or NSCLC) but increased
with the severity of the organ failures. Of 27 hospital
survivors, only 4 received further specific treatment for
lung cancer. Our findings suggest that patients with
advanced lung cancer and non-infectious iatrogenic
complications may benefit from MCIU admission.
Further studies of patients selected to MICU admission
are needed to assess long-term mortality, quality of life,
ability to continue chemotherapy and socio-economic
cost.
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